Newsletter Tool

To view this email as a web page, click here

Today's Rundown

After nearly $1B in research funding, Moderna takes $1.5B coronavirus vaccine order from U.S.
Alphabet’s Verily opens own lab to speed up COVID testing
Healthcare workers lose out on COVID sick leave protections, federal watchdog says
Parents are struggling with school and child care options amid COVID-19. Maven rolled out an online tool to help
Researchers call out Gilead over diversity of remdesivir trials
Kaiser Permanente announces $63M for contact tracing in California
AstraZeneca bumps up vaccine deal with Brazil to $360M with more doses, licensing rights
Healthcare roundup: BCBSRI expands no-cost Medicare Advantage benefits
Biopharma roundup: IAVI, Wellcome push for global antibody access; Verily shoots for speedier testing with new lab, Thermo Fisher tech

Featured Story

After nearly $1B in research funding, Moderna takes $1.5B coronavirus vaccine order from U.S.

By Eric Sagonowsky

Through its COVID-19 vaccine partnership with the U.S. government, Moderna picked up nearly $1 billion in research aid. Now, it's joining a long list of other companies to take a supply order from the federal government—locking up $1.5 billion in the process.

Alphabet’s Verily opens own lab to speed up COVID testing

By Ben Adams

The buzzy life sciences company Verily is looking to speed up COVID testing with a new lab based at its native South San Francisco.

Healthcare workers lose out on COVID sick leave protections, federal watchdog says

By Tina Reed

A new report from a federal watchdog finds a temporary rule issued by the Department of Labor has left many healthcare workers without COVID sick-leave protections passed by Congress back in March.

Parents are struggling with school and child care options amid COVID-19. Maven rolled out an online tool to help

By Heather Landi

Working parents face touch decisions about how their children will soon return to school—whether it will be virtually or in person. Women and family health startup Maven developed an evidence-based tool to help patients assess the risks and benefits of different school and child care options.

Researchers call out Gilead over diversity of remdesivir trials

By Nick Paul Taylor

Researchers have called for sponsors of COVID-19 clinical trials to run more diverse studies. The call follows an analysis of Gilead’s remdesivir clinical trials that found the studies “failed to provide equal representation of Black, Latinx and Native Americans.”

Kaiser Permanente announces $63M for contact tracing in California

By Tina Reed

The non-profit integrated healthcare giant said the funding will be in the form of charitable grant funding to the Public Health Institute to create agile community health teams hired from communities disproportionately affected by COVID-19.

AstraZeneca bumps up vaccine deal with Brazil to $360M with more doses, licensing rights

By Kyle Blankenship

In an effort to supercharge distribution of its vaccine hopeful, British drugmaker AstraZeneca has spanned the globe to ink a slew of national supply deals. Now, after inking a more limited pact in June, AstraZeneca and Brazil are ramping up their partnership to make even more doses of the shot.

Healthcare roundup: BCBSRI expands no-cost Medicare Advantage benefits

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

Biopharma roundup: IAVI, Wellcome push for global antibody access; Verily shoots for speedier testing with new lab, Thermo Fisher tech

By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner

IAVI and Wellcome called for industry partnerships and new tech to ensure global access to antibody treatments. Verily set up a new lab to hustle along COVID testing. ANA Therapeutics got the OK to run human trials on a tapeworm med in COVID-19. SAB Biotherapeutics launched a polyclonal antibody phase 1. Plus, Fauci slammed Russia's newly-approved vaccine.

COVID-19 Tracker